A Study to Evaluate the Safety and Efficacy of Humia Inj. in Patients With Symptomatic Osteoarthritis of the Knee

NCT ID: NCT02893098

Last Updated: 2018-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

232 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multi-Centre, Parallel, Double-Blind, Active comparator, Randomised phase III Clinical Trial

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of Knee

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Humia inj.

Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.

Group Type EXPERIMENTAL

Humia inj.

Intervention Type DRUG

Single injection of 3mL Humia inj.

Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks

High Hyal Plus inj.

Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks

Group Type ACTIVE_COMPARATOR

High hyal Plus inj.

Intervention Type DRUG

Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Humia inj.

Single injection of 3mL Humia inj.

Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks

Intervention Type DRUG

High hyal Plus inj.

Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary knee osteoarthritis confirmed clinically and radiologically according to American College of Rheumatology criteria have joint pain
* Kellgren-Lawrence Grade Ⅰ to Ⅲ confirmed radiologically within 6 months
* Knee pain under weight-bearing pain(100mm-VAS) greater than 40mm
* Able to walk without assistive devices
* Patients willing and able to provide signed informed consent after the nature of the study has been explained

Exclusion Criteria

* Body Mass Index (BMI) \> 32
* History of rheumatoid arthritis or other inflammatory arthritis in knee articular cavity
* Systemic Intravenous Steroid injection within 1 month, intra-articular corticosteroid injection within 3 months or hyaluronate injection within 6 months
* Has clinically severe tense effusion of the target knee diagnosed Positive according to Patella tap test
* Undergo Knee Replacement Surgery of the target knee
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Huons Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Huons

Ansan-si, Gyeonggi-do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HU-025 P3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.